KOL Perspectives: BTK Inhibitors in RA

KOL Perspectives: BTK Inhibitors in RA


This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics -

  • Awareness and potential of BTK inhibitors in RA
  • Perceptions of BMS-986142’s Phase IItrial design
  • Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA
Key Highlights
  • Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data
  • KOLs were divided over BMS-986142’s ability to achieve ACR70 by Week 12 in a refractory patient population
  • For the majority of KOLs, poseltinib’s discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs).
, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Executive Summary
Research Panel Composition
Results & Implications

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook